Last updated on August 2017

A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)


Brief description of study

The purpose of this study is to assess the safety and pharmacokinetics of niraparib when administered in combination with an androgen receptor (AR)-targeted therapy (apalutamide or abiraterone acetate plus prednisone) in adult men with metastatic castration resistant prostate cancer (mCRPC) who may or may not have deoxyribonucleic acid (DNA)-repair anomalies.

Clinical Study Identifier: NCT02924766

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Cedars-Sinai Medical Center

Cedars-Sinai Medical Center
West Hollywood, CA United States
  Connect »

Norton Healthcare

Norton Healthcare
Louisville, KY United States
  Connect »

Oregon Health & Science University

Oregon Health & Science University
Portland, OR United States
  Connect »

Carolina Urologic Research Center

Carolina Urologic Research Center
Myrtle Beach, SC United States
  Connect »

British Columbia Cancer Agency (BCCA) ...

British Columbia Cancer Agency (BCCA) - Vancouver Prostate Centre
Vancouver, BC Canada
  Connect »

CHUM - Centre hospitalier universitaire ...

CHUM - Centre hospitalier universitaire de Montreal
Montreal, QC Canada
  Connect »